Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.66 USD
Change Today -0.22 / -2.79%
Volume 845.0K
BDSI On Other Exchanges
Symbol
Exchange
Frankfurt
As of 1:58 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

biodelivery sciences intl (BDSI) Snapshot

Open
$7.83
Previous Close
$7.88
Day High
$8.02
Day Low
$7.49
52 Week High
09/12/14 - $18.48
52 Week Low
06/30/15 - $7.17
Market Cap
401.5M
Average Volume 10 Days
880.7K
EPS TTM
$-1.17
Shares Outstanding
52.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIODELIVERY SCIENCES INTL (BDSI)

biodelivery sciences intl (BDSI) Related Businessweek News

No Related Businessweek News Found

biodelivery sciences intl (BDSI) Details

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer marketed under the BREAKYL name in Europe and PAINKYL name in Taiwan; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA for the treatment of chronic pain. The company also develops Clonidine Topical Gel, which is in Phase III clinical trial to treat painful diabetic neuropathy and other indications; and buprenorphine depot injection. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Arcion Therapeutics, Inc.; Evonik Corporation; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

29 Employees
Last Reported Date: 03/16/15
Founded in 1997

biodelivery sciences intl (BDSI) Top Compensated Officers

Chief Executive Officer, President, Chief Sci...
Total Annual Compensation: $751.4K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $370.9K
Executive Vice President of Product Developme...
Total Annual Compensation: $434.2K
Compensation as of Fiscal Year 2014.

biodelivery sciences intl (BDSI) Key Developments

BioDelivery Sciences International, Inc. Appoints Enoch Bortey as Vice President of Clinical Biostatistics and Data Systems

BioDelivery Sciences International, Inc. announced that Enoch Bortey, Ph.D., has joined the company as Vice President of Clinical Biostatistics and Data Systems. In this capacity, Dr. Bortey will be responsible for overseeing the global design and development of the biostatistics function, translating the development strategies into tactical statistical plans to support product development objectives. He will report to Dr. Andrew Finn, Executive Vice President of Product Development. Dr. Bortey brings over 24 years of pharmaceutical industry drug development experience to the BDSI development team. He most recently was Senior Vice President of Clinical Operations and Biometrics at Salix Pharmaceuticals where over an 8 year period he progressed in responsibility from a role in biometrics to a combined role in biometrics and clinical operations. Prior to joining Salix, Dr. Bortey was Senior Director of Biostatistics for Nabi Biopharmaceuticals.

BioDelivery Sciences Seeks Acquisitions

BioDelivery Sciences International, Inc. (NasdaqCM:BDSI) intends to use proceeds from the sales of securities for the clinical and regulatory advancement of its product candidates; for commercialization of its products, including potential sales and marketing of products on its own behalf; to support of its partnered products; for potential acquisitions of new technologies and products or related companies, and to meet working capital needs.

BioDelivery Sciences International, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 10:45 AM

BioDelivery Sciences International, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 10:45 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Mark A. Sirgo, Chief Executive Officer, President, Chief Scientific Officer, Executive Director and Member of Executive Subcommittee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDSI:US $7.66 USD -0.22

BDSI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.00 USD -0.12
Galena Biopharma Inc $1.65 USD -0.0465
IntelGenx Technologies Corp C$0.75 CAD 0.00
Skyepharma PLC 278.75 GBp -3.25
Zogenix Inc $19.62 USD +1.13
View Industry Companies
 

Industry Analysis

BDSI

Industry Average

Valuation BDSI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.1x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODELIVERY SCIENCES INTL, please visit www.bdsi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.